Immunic Inc. (IMUX) said that its selective oral DHODH inhibitor, IMU-838, has shown evidence of clinical activity in hospitalized patients with moderate COVID-19.
The company noted that primary and key secondary endpoints were not evaluable due to the very low rates of serious complications in the population of hospitalized patients with moderate COVID-19.
The company said high-risk patients and patients aged over 65 years experienced a more substantial treatment effect of IMU-838.
The company noted that an anti-viral effect of IMU-838 on SARS-CoV-2 was observed by viral titers at the end of the treatment period (day 14) and at the end of the study (day 28). An anti-inflammatory effect of IMU-838 was observed based on a more effective reduction of C-reactive protein (CRP), a well-known marker for inflammation in the blood, in IMU-838 treated patients, as compared to placebo.
A more effective reduction of D-dimer, a well-known prognostic disease marker for COVID-19, was observed in IMU-838 treated patients, as compared to placebo.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.